Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study - PubMed (original) (raw)
Comparative Study
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study
Natalia Acosta-Baena et al. Lancet Neurol. 2011 Mar.
Abstract
Background: Mild cognitive impairment (MCI) and pre-MCI have been proposed as stages preceding Alzheimer's disease (AD) dementia. We assessed descendants of individuals with a mutation in presenilin 1 (PSEN1) that causes familial AD, with the aim of identifying distinct stages of clinical progression to AD dementia.
Methods: We retrospectively studied a cohort of descendants of carriers of the PSEN1 E280A mutation. Pre-dementia cognitive impairment was defined by a score 2 SD away from normal values in objective cognitive tests, and was subdivided as follows: asymptomatic pre-MCI was defined by an absence of memory complaints and no effect on activities of daily living; symptomatic pre-MCI was defined by a score on the subjective memory complaints checklist higher than the mean and no effect on activities of daily living; and MCI was defined by a score on the subjective memory complaints checklist higher than the mean, with no effect on basic activities of daily living and little or no effect on complex daily activities. Dementia was defined according to the diagnostic and statistical manual of mental disorders, fourth edition. Reference mean scores were those of participants who did not carry the PSEN1 E280A mutation. We used the Turnbull survival analysis method to identify ages at onset of each stage of the disease. We measured the time from birth until onset of the three pre-dementia stages, dementia, and death, and assessed decline in cognitive domains for each stage.
Findings: Follow-up was from Jan 1, 1995, to Jan 27, 2010. 1784 patients were initially identified, 449 of whom were PSEN1 E280A carriers who had complete clinical follow-up. Median age at onset was 35 years (95% CI 30-36) for asymptomatic pre-MCI, 38 years (37-40) for symptomatic pre-MCI, 44 years (43-45) for MCI, and 49 years (49-50) for dementia. The median age at death was 59 years (95% CI 58-61). The median time of progression from asymptomatic to symptomatic pre-MCI was 4 years (95% CI 2-8), from symptomatic pre-MCI to MCI was 6 years (4-7), from MCI to dementia was 5 years (4-6), and from dementia to death was 10 years (9-12). The cognitive profile was predominantly amnestic and was associated with multiple domains. Affected domains showed variability in initial stages, with some transient recovery in symptomatic pre-MCI followed by continuous decline.
Interpretation: Clinical deterioration can be detected as measurable cognitive impairment around two decades before dementia onset in PSEN1 E280A carriers. Onset and progression of pre-dementia stages should be considered in the investigation and use of therapeutic interventions for familial AD.
Funding: Departamento Administrativo de Ciencia, Tecnología e Innovación, COLCIENCIAS, Republic of Colombia.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Comment in
- Setting the stage for prevention of familial Alzheimer's disease.
Ringman JM. Ringman JM. Lancet Neurol. 2011 Mar;10(3):200-1. doi: 10.1016/S1474-4422(10)70328-8. Epub 2011 Feb 3. Lancet Neurol. 2011. PMID: 21296021 No abstract available.
Similar articles
- Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
Aguirre-Acevedo DC, Jaimes-Barragán F, Henao E, Tirado V, Muñoz C, Reiman EM, Tariot PN, Langbaum JB, Lopera F. Aguirre-Acevedo DC, et al. Int Psychogeriatr. 2016 Mar;28(3):503-10. doi: 10.1017/S1041610215001660. Epub 2015 Oct 19. Int Psychogeriatr. 2016. PMID: 26478578 - Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation.
Sepulveda-Falla D, Glatzel M, Lopera F. Sepulveda-Falla D, et al. J Alzheimers Dis. 2012;32(1):1-12. doi: 10.3233/JAD-2012-120907. J Alzheimers Dis. 2012. PMID: 22766738 Review. - Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM. Fleisher AS, et al. Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6. Lancet Neurol. 2012. PMID: 23137949 Free PMC article. - Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study.
Aguirre-Acevedo DC, Lopera F, Henao E, Tirado V, Muñoz C, Giraldo M, Bangdiwala SI, Reiman EM, Tariot PN, Langbaum JB, Quiroz YT, Jaimes F. Aguirre-Acevedo DC, et al. JAMA Neurol. 2016 Apr;73(4):431-8. doi: 10.1001/jamaneurol.2015.4851. JAMA Neurol. 2016. PMID: 26902171 Free PMC article. - The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
Ayutyanont N, Langbaum JB, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, Ward M, Aguirre C, Acosta-Baena N, Madrigal L, Muñoz C, Tirado V, Moreno S, Tariot PN, Lopera F, Reiman EM. Ayutyanont N, et al. J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927. J Clin Psychiatry. 2014. PMID: 24816373 Free PMC article. Review.
Cited by
- Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer's disease.
Pardilla-Delgado E, Torrico-Teave H, Sanchez JS, Ramirez-Gomez LA, Baena A, Bocanegra Y, Vila-Castelar C, Fox-Fuller JT, Guzmán-Vélez E, Martínez J, Alvarez S, Ochoa-Escudero M, Lopera F, Quiroz YT. Pardilla-Delgado E, et al. Brain Commun. 2021 May 10;3(2):fcab101. doi: 10.1093/braincomms/fcab101. eCollection 2021. Brain Commun. 2021. PMID: 34095834 Free PMC article. - Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease.
Littau JL, Velilla L, Hase Y, Villalba-Moreno ND, Hagel C, Drexler D, Osorio Restrepo S, Villegas A, Lopera F, Vargas S, Glatzel M, Krasemann S, Quiroz YT, Arboleda-Velasquez JF, Kalaria R, Sepulveda-Falla D. Littau JL, et al. Brain Pathol. 2022 Nov;32(6):e13097. doi: 10.1111/bpa.13097. Epub 2022 Jun 13. Brain Pathol. 2022. PMID: 35695802 Free PMC article. - Structural imaging in early pre-states of dementia.
Smith CD. Smith CD. Biochim Biophys Acta. 2012 Mar;1822(3):317-24. doi: 10.1016/j.bbadis.2011.07.002. Epub 2011 Jul 14. Biochim Biophys Acta. 2012. PMID: 21777674 Free PMC article. Review. - The genetics of Alzheimer's disease.
Barber RC. Barber RC. Scientifica (Cairo). 2012;2012:246210. doi: 10.6064/2012/246210. Epub 2012 Dec 31. Scientifica (Cairo). 2012. PMID: 24278680 Free PMC article. Review. - Clinical genetics of Alzheimer's disease.
Zou Z, Liu C, Che C, Huang H. Zou Z, et al. Biomed Res Int. 2014;2014:291862. doi: 10.1155/2014/291862. Epub 2014 May 13. Biomed Res Int. 2014. PMID: 24955352 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical